Table 1 Correlations between dorsal and ventral gmvs, pain measures, opioid dose, and opioid use duration.

From: Cross-sectional relationships between spinal cord gray matter volume and pain in individuals with fibromyalgia and opioid use

 

GMV

Opioid dose (MME)

Opioid use duration

Pain

duration

Pain

severity

Pain

interference

CPT time

(sec)

r

p

r

p

r

p

r

p

r

p

r

p

FMO

V

0.07

0.761

0.05

0.808

−0.16

0.419

0.49

0.012

0.55

0.004

0.60

0.001

 

D

0.06

0.788

−0.04

0.868

−0.13

0.525

0.43

0.028

0.50

0.010

0.55

0.004

FMN

V

    

0.43

0.015

−0.11

0.572

0.12

0.544

−0.04

0.854

 

D

    

0.37

0.041

−0.13

0.505

0.10

0.608

−0.08

0.682

HC

V

          

−0.03

0.891

 

D

          

−0.05

0.801

  1. Spearman’s bivariate correlations were conducted to evaluate within-group relationships between ventral and dorsal gray matter volumes versus pain sensitivity and clinical measures of pain. FMO individuals with fibromyalgia taking opioids, FMN individuals with fibromyalgia not taking opioids, HC healthy controls, GMV gray matter volume, V Ventral, D Dorsal, CPT cold pressor test, MME morphine milligram equivalents.
Back to article page